How were Impel Pharmaceuticals' earnings last quarter?

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.42. The firm earned $0.09 million during the quarter.

When did Impel Pharmaceuticals IPO?

Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO.

NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

→ Start loving Mondays like this (From DTI) (Ad)

Free IMPL Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.04
▼
$0.84
52-Week Range: N/A

Volume: 720,000 shs
Average Volume: 682,655 shs
Market Capitalization: $956,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Earnings Headlines Insider Trades Ownership Short Interest Social Media

Get Impel Pharmaceuticals alerts:

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

Ad DTI

This company has increased its dividend every year for 54 years

Click here to get them (for Free).

IMPL Stock News Headlines

March 13, 2024 | finance.yahoo.com

Impel Pharmaceuticals Inc. (IMPLQ)

December 20, 2023 | markets.businessinsider.com

Impel Pharma Mulls Sale, Signs Stalking Horse Deal; Files For Chapter 11 Protection

April 19, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

December 20, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale

November 6, 2023 | bizjournals.com

Adrian Adams steps down as CEO of Seattle's Impel Pharmaceuticals

October 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Impel Pharmaceuticals (IMPL) and Relay Therapeutics (RLAY)

October 5, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

September 14, 2023 | markets.businessinsider.com

Impel Pharmaceuticals (IMPL) Receives a Hold from JonesTrading

April 19, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

September 8, 2023 | msn.com

Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?

August 22, 2023 | markets.businessinsider.com

JonesTrading Reaffirms Their Hold Rating on Impel Pharmaceuticals (IMPL)

August 16, 2023 | marketwatch.com

Impel Pharma Shares Tumble 46% After Breaching Terms of Credit Agreement

August 16, 2023 | msn.com

Impel Pharma (NASDAQ:IMPL) Plummets on Viability Concerns

August 16, 2023 | investorplace.com

Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?

July 5, 2023 | theglobeandmail.com

Biotech Catches Major Premarket Bid

July 3, 2023 | finance.yahoo.com

84P.SG - Impel Pharmaceuticals Inc

June 21, 2023 | benzinga.com

Director at Impel Pharmaceuticals Acquires Company Stock Options Worth 13,222 Shares

June 21, 2023 | benzinga.com

Impel Pharmaceuticals Board Member Awarded $15K Worth of Stock Options

June 21, 2023 | benzinga.com

Impel Pharmaceuticals Director Awarded $15K Worth of Stock Options

June 15, 2023 | finance.yahoo.com

Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society

May 17, 2023 | uk.finance.yahoo.com

Impel Pharmaceuticals Inc. (IMPL)

May 13, 2023 | finance.yahoo.com

Impel Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations

May 12, 2023 | msn.com

Recap: Impel Pharmaceuticals Q1 Earnings

May 12, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023 | msn.com

Earnings Outlook For Impel Pharmaceuticals

May 10, 2023 | msn.com

Impel Pharmaceuticals gets new CFO

May 10, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

See More Headlines

Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMPL
CUSIP: N/A
CIK: 1445499
Web: www.Impelnp.com
Phone: 206-568-1466
Fax: N/A
Employees: 160
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,310,000.00
Net Margins: -353.93%
Pretax Margin: -353.93%
Return on Equity: N/A
Return on Assets: -127.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.19
Quick Ratio: 0.13

Sales & Book Value

Annual Sales: $20.99 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.86) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 23,900,000
Free Float: 22,418,000
Market Cap: $956,000.00
Optionable: Not Optionable
Beta: 1.17

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Leonard S. Paolillo (Age 44)
Interim President & CEO
Comp: $523.97k
Dr. John D. Hoekman Ph.D. (Age 42)
Co-Founder and Chief Technology & Development Officer
Mr. Michael W. Kalb CPA (Age 52)
Chief Financial Officer
Ms. Jennifer L. Berman
Vice President of Marketing
Ms. Sarah Wille
Vice President of Human Resources
Dr. Lynn C. Gold Ph.D. (Age 66)
Senior Vice President of Regulatory
Mr. Scott Youmans (Age 56)
Senior Vice President of Technical Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

IMPL Stock Analysis - Frequently Asked Questions

How were Impel Pharmaceuticals' earnings last quarter?: Impel Pharmaceuticals Inc. (NASDAQ:IMPL) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.42. The firm earned $0.09 million during the quarter.
When did Impel Pharmaceuticals IPO?: Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO.

This page (NASDAQ:IMPL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

IMPL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

IMPL Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info